Monoclonal antibodies directed to the HER2 receptor
US6387371B1 · kind B1 · utility
137Cited by
29References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 1999 |
| Grant date | May 14, 2002 |
| Priority date | — |
| Expiry date | Jun 25, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.